Literature DB >> 15541630

Pharmacological management of challenging behavior of individuals with intellectual disability.

Jane A McGillivray1, Marita P McCabe.   

Abstract

In many Westernized countries, including Australia, concerns about the use of psychotropic drugs to manage the challenging behavior of individuals with intellectual disability have resulted in the development of legislative and procedural controls. Although these constraints may limit indiscriminate use, employing medication remains a common practice. This study examined information about 873 individuals (566 males, 307 females) who were the subjects of reports to the Intellectual Disability Review Panel in March 2000 concerning the use of chemical restraint. A high proportion of people with intellectual disability were reported to have received drugs for purposes of behavioral restraint. The range of drugs was extensive, although those from the antipsychotic class were the most frequently reported. Many individuals concurrently received more than one type of drug or more than one drug from the same drug class. More males than females and more older than younger individuals were administered medication. A relationship between gender and age was apparent, with younger males but older females dominating. The use of drugs to mange the behavior of people with intellectual disability may at times be warranted. However, it is important that the extent and type of drug use, as well as the characteristics of those who are medicated, be subject to ongoing scrutiny.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15541630     DOI: 10.1016/j.ridd.2004.03.001

Source DB:  PubMed          Journal:  Res Dev Disabil        ISSN: 0891-4222


  6 in total

Review 1.  Polypharmacy in the treatment of subjects with intellectual disability.

Authors:  Frank Häβler; Johannes Thome; Olaf Reis
Journal:  J Neural Transm (Vienna)       Date:  2014-05-25       Impact factor: 3.575

2.  International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities.

Authors:  Shoumitro Deb; Henry Kwok; Marco Bertelli; Luis Salvador-Carulla; Elspeth Bradley; Jennifer Torr; Jarret Barnhill
Journal:  World Psychiatry       Date:  2009-10       Impact factor: 49.548

Review 3.  Prescribing psychotropic drugs to adults with an intellectual disability.

Authors:  Julian N Trollor; Carmela Salomon; Catherine Franklin
Journal:  Aust Prescr       Date:  2016-08-01

4.  Drug burden index to define the burden of medicines in older adults with intellectual disabilities: An observational cross-sectional study.

Authors:  Juliette O'Connell; Éilish Burke; Niamh Mulryan; Claire O'Dwyer; Clare Donegan; Philip McCallion; Mary McCarron; Martin C Henman; Máire O'Dwyer
Journal:  Br J Clin Pharmacol       Date:  2018-01-05       Impact factor: 4.335

5.  Recognition and treatment of mood dysregulation in adults with intellectual disability.

Authors:  Jason Noel
Journal:  Ment Health Clin       Date:  2018-11-01

6.  Community-Based Support and Social Services and Their Association with Frailty Factors in Older People with Intellectual Disability and Affective and Anxiety Disorders: A Swedish National Population-Based Register Study.

Authors:  Nadia El Mrayyan; Christina Bökberg; Jonas Eberhard; Gerd Ahlström
Journal:  Community Ment Health J       Date:  2021-11-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.